灯盏花素治疗急性脑梗死对超敏C反应蛋白的影响及疗效机制  

Changes of high sensitivity C-reactive protein level after Breviscapine injection treatment in acute ischemic stroke patients and its mechanism

作　　者：左鹰[1] 于东明[1] 

机构地区：[1]首都医科大学附属北京天坛医院急诊科,北京100050

出　　处：《中国急救医学》2008年第2期107-109,共3页Chinese Journal of Critical Care Medicine

摘　　要：目的探讨灯盏花素治疗急性脑梗死对超敏C反应蛋白(hsCRP)的影响及疗效机制。方法采用酶联免疫吸附法(ELLSA法)分别在第2、7、14天检测治疗组、对照组、健康对照组血清hsCRP水平。观察并记录病例治疗前及治疗后第7、14、30天的神经功能评分。结果急性脑梗死患者血清hsCRP水平较健康对照组明显增高,血清hsCRP水平与神经功能缺损程度呈正相关;治疗组血清hsCRP水平在治疗后第7、14天较对照组明显降低(P<0.05),神经功能评分在治疗后第7、14、30天时与对照组比较差异有统计学意义(P<0.05,P<0.01);治疗组未见明显不良反应。结论血清hsCRP水平与脑梗死及病情严重程度密切相关,是脑梗死的危险因素。灯盏花素治疗急性脑梗死时可降低hsCRP水平,抑制急性脑梗死后的血管炎性反应,减轻神经功能障碍,改善脑梗死患者预后。灯盏花素治疗急性脑梗死具有一定的疗效及安全性。Objective To analyze the changes of C - reactive protein level after Breviscapine injection treatment for acute ischemic stroke patients and its mechanism. Methods The serum high sensitivity C - reactive protein （ hs - CRP） levels were measured at 2, 7,14 d by using particle - enhanced immunoturbidimetric test in the patients of treatment group （ n = 40, with Breviscapine injection treatment） and in the patients of control group （ n = 40, without Breviscapine injection treatment） and in healthy control group（ n = 40）. National institutes of health stroke scale（NIHSS） , Barthel Index（BI） were evaluated before the treatment and 7, 14,30 d after the treatment. Results Acute ischemic stroke patients had a significantly higher level of hs - CRP compared with healthy subjects （ P 〈 0. 05 ） and positive correlation was observed between the hs -CRP level and nerve functional insufficient status;The serum hs -CRP of treatment group was obviously lower than that of control group （P 〈0.05 ） on the 7 th, 14 th day; 7,14 and 30 days after treatment, the scores of NIHSS were lower in treatment group than in control group （ P 〈 0. 05 or P 〈 0. 01 ） , while the scores of BI were higher （ P 〈 0. 05 or P 〈 0. 01 ） ; No adverse reactions were observed in the treatment group. Conclusion The serum hs - CRP level closely related to acute ischemic stroke and is the risk factor. Treatment with Breviseapine can decrease the level of hs -CRP, inhibit the vascular inflammatory, reaction, relieve neurological dysfunction and improve the prognosis of acute ischemic stroke patients. Breviscapine injection treatment is effective and safe for acute ischemic stoke.

关 键 词：灯盏花素 脑梗死 超敏C反应蛋白 疗效 

分 类 号：R277.7[医药卫生—中医学]